Company intelligence / Profile preview

Santersus

Ownership: Private
Development stage: Clinical

Overview

Santersus’ NucleoCapture device has demonstrated the ability to remove up to 99% of circulating NETs in animal models of sepsis, resulting in improved physiological status and survival. Ex vivo studies have shown potential for restoring previously discarded lungs for transplantation. The technology is being explored as an adjunctive treatment across multiple acute and chronic inflammatory conditions.

Therapeutic areas: OncologyPulmonologyImmunologyOtherNeurologyInfectious Diseases
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

NucleoCapture

Clinical

Indications: Sepsis, Transplantation, Cancer, Autoimmune diseases

1 more asset in the full pipeline.

Request access →

Partnerships

VolitionRx Limited (collaboration on diagnostic monitoring using Nu.Q nucleosome assay)

Beyond the preview

Go deeper on Santersus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Santersus.

Explore the full profile